Amgen Inc (AMGN) stock
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3026% above fair value
$457.93−4.39 (-0.95%)
Close on Nov 17, 2026Market cap $247.57BP/E 26.5Yield 2.11%
Amgen cash
Cash and short-term investments held at the end of each period.
Amgen's cash was $13.19B at Sep 30, 2026. For fiscal 2025 it was $9.13B, down 23.8% from the year before. Over ten years it grew 8.2% a year on average. The highest annual figure on record is $41.68B in fiscal 2017.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.13B | -23.8% |
| FY2024 | Dec 31, 2024 | $11.97B | +9.4% |
| FY2023 | Dec 31, 2023 | $10.94B | +17.6% |
| FY2022 | Dec 31, 2022 | $9.31B | +15.8% |
| FY2021 | Dec 31, 2021 | $8.04B | -24.5% |
| FY2020 | Dec 31, 2020 | $10.65B | +19.5% |
| FY2019 | Dec 31, 2019 | $8.91B | -69.6% |
| FY2018 | Dec 31, 2018 | $29.30B | -29.7% |
| FY2017 | Dec 31, 2017 | $41.68B | +1186.0% |
| FY2016 | Dec 31, 2016 | $3.24B | -21.8% |
| FY2015 | Dec 31, 2015 | $4.14B | +11.1% |
| FY2014 | Dec 31, 2014 | $3.73B | -1.9% |
| FY2013 | Dec 31, 2013 | $3.81B | +16.8% |
| FY2012 | Dec 31, 2012 | $3.26B | -53.1% |
| FY2011 | Dec 31, 2011 | $6.95B | +111.3% |
| FY2010 | Dec 31, 2010 | $3.29B | +14.0% |
| FY2009 | Dec 31, 2009 | $2.88B | +62.6% |
| FY2008 | Dec 31, 2008 | $1.77B | -12.4% |
| FY2007 | Dec 31, 2007 | $2.02B | +57.8% |
| FY2006 | Dec 31, 2006 | $1.28B | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $13.19B | +39.7% |
| Q2 FY2026 | Jun 30, 2026 | $13.99B | +74.3% |
| Q1 FY2026 | Mar 31, 2026 | $12.04B | +36.6% |
| Q4 FY2025 | Dec 31, 2025 | $9.13B | -23.8% |
| Q3 FY2025 | Sep 30, 2025 | $9.45B | +4.8% |
| Q2 FY2025 | Jun 30, 2025 | $8.03B | -13.7% |
| Q1 FY2025 | Mar 31, 2025 | $8.81B | -9.3% |
| Q4 FY2024 | Dec 31, 2024 | $11.97B | +9.4% |
| Q3 FY2024 | Sep 30, 2024 | $9.01B | -74.1% |
| Q2 FY2024 | Jun 30, 2024 | $9.30B | -72.8% |
| Q1 FY2024 | Mar 31, 2024 | $9.71B | -69.2% |
| Q4 FY2023 | Dec 31, 2023 | $10.94B | +17.6% |
| Q3 FY2023 | Sep 30, 2023 | $34.74B | +202.7% |
| Q2 FY2023 | Jun 30, 2023 | $34.25B | +376.8% |
| Q1 FY2023 | Mar 31, 2023 | $31.56B | +382.3% |
| Q4 FY2022 | Dec 31, 2022 | $9.31B | +15.8% |
| Q3 FY2022 | Sep 30, 2022 | $11.48B | -11.2% |
| Q2 FY2022 | Jun 30, 2022 | $7.18B | -32.0% |
| Q1 FY2022 | Mar 31, 2022 | $6.54B | -38.5% |
| Q4 FY2021 | Dec 31, 2021 | $8.04B | -35.0% |
| Q3 FY2021 | Sep 30, 2021 | $12.92B | +13.1% |
| Q1 FY2021 | Mar 31, 2021 | $10.57B | +31.9% |
| Q4 FY2020 | Dec 31, 2020 | $10.65B | +19.5% |
| Q3 FY2020 | Sep 30, 2020 | $12.36B | -43.2% |
| Q2 FY2020 | Jun 30, 2020 | $11.42B | -56.6% |
| Q1 FY2020 | Mar 31, 2020 | $8.01B | -72.7% |
| Q4 FY2019 | Dec 31, 2019 | $8.91B | -70.2% |
| Q2 FY2019 | Jun 30, 2019 | $21.76B | -26.0% |
| Q1 FY2019 | Mar 31, 2019 | $26.30B | +170.0% |
| Q4 FY2018 | Dec 31, 2018 | $29.30B | -29.7% |
| Q3 FY2018 | Sep 30, 2018 | $29.92B | +897.4% |
| Q2 FY2018 | Jun 30, 2018 | $29.40B | +1018.1% |
| Q1 FY2018 | Mar 31, 2018 | $9.74B | +190.1% |
| Q4 FY2017 | Dec 31, 2017 | $41.68B | +1186.0% |
| Q3 FY2017 | Sep 30, 2017 | $3.00B | -13.9% |
| Q2 FY2017 | Jun 30, 2017 | $2.63B | -0.0% |
| Q1 FY2017 | Mar 31, 2017 | $3.36B | – |
| Q4 FY2016 | Dec 31, 2016 | $3.24B | – |
| Q3 FY2016 | Sep 30, 2016 | $3.49B | – |
| Q2 FY2016 | Jun 30, 2016 | $2.63B | – |
See a number that looks wrong?